Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) have been assigned an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $8.33.

Several research firms recently commented on TNXP. Roth Capital raised Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Friday, August 18th. They noted that the move was a valuation call. Dawson James reaffirmed a “buy” rating and set a $9.00 target price on shares of Tonix Pharmaceuticals Holding Corp. in a report on Wednesday, August 23rd. Aegis began coverage on Tonix Pharmaceuticals Holding Corp. in a report on Monday, June 26th. They set a “buy” rating and a $10.00 target price on the stock. ValuEngine raised Tonix Pharmaceuticals Holding Corp. from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Drexel Hamilton began coverage on Tonix Pharmaceuticals Holding Corp. in a report on Tuesday, August 22nd. They set a “buy” rating on the stock.

ILLEGAL ACTIVITY WARNING: “Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Recommendation of “Buy” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/17/tonix-pharmaceuticals-holding-corp-tnxp-receives-average-recommendation-of-buy-from-analysts.html.

In other Tonix Pharmaceuticals Holding Corp. news, Director Ernest Mario sold 6,105 shares of the stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $4.28, for a total transaction of $26,129.40. Following the transaction, the director now owns 63,073 shares in the company, valued at $269,952.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Seth Lederman purchased 20,000 shares of the stock in a transaction on Tuesday, June 20th. The shares were acquired at an average price of $4.22 per share, for a total transaction of $84,400.00. Following the transaction, the chief executive officer now directly owns 7,912 shares of the company’s stock, valued at approximately $33,388.64. The disclosure for this purchase can be found here. Insiders have acquired 50,000 shares of company stock worth $188,050 in the last quarter. 4.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Citadel Advisors LLC purchased a new position in Tonix Pharmaceuticals Holding Corp. during the first quarter worth approximately $119,000. Dialectic Capital Management LP purchased a new position in Tonix Pharmaceuticals Holding Corp. during the first quarter worth approximately $187,000. Vanguard Group Inc. boosted its position in Tonix Pharmaceuticals Holding Corp. by 28.8% during the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock worth $799,000 after purchasing an additional 41,264 shares in the last quarter. Finally, B. Riley Financial Inc. purchased a new position in Tonix Pharmaceuticals Holding Corp. during the second quarter worth approximately $1,637,000. Institutional investors own 28.80% of the company’s stock.

Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP) traded up 3.20% during midday trading on Friday, hitting $4.19. The company’s stock had a trading volume of 153,977 shares. The company’s market cap is $31.46 million. The company’s 50-day moving average is $3.64 and its 200 day moving average is $3.74. Tonix Pharmaceuticals Holding Corp. has a one year low of $0.33 and a one year high of $9.40.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last posted its earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.13. On average, analysts predict that Tonix Pharmaceuticals Holding Corp. will post ($3.02) EPS for the current year.

Tonix Pharmaceuticals Holding Corp. Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Analyst Recommendations for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.